DeBeurs.nl

voda 5 augustus 2009 18:24

0

Philips werkt mee aan gentherapie
5 augustus 2009, 18:17 | ANP
EINDHOVEN (AFN) - Technologieconcern Philips gaat samen met een Amerikaans biotechbedrijf werken aan een betere behandeling van een zeldzame erfelijke leveraandoening. Het bedrijf zet daarbij ultrageluid in om de opname van therapeutische genen doelgerichter te maken.

Dat maakte Philips woensdag bekend. Partner is GlyGenix Therapeutics uit de Amerikaanse staat Connecticut. De partijen gaan een haalbaarheidsonderzoek verrichten naar ultrasone technieken voor gentherapie.

Het is voor het eerst dat Philips zich samen met een biotechbedrijf begeeft in de onderzoekswereld van gentherapie. GlyGenix heeft zich gespecialiseerd in de therapieën voor de aandoening waarvoor beide partijen het onderzoek verrichten.

Bloedsuikerspiegel

Mensen met de chronische leveraandoening, ook wel GSD1a genoemd, kunnen hun bloedsuikerspiegels niet goed reguleren. Voor jongvolwassenen kunnen daarbij andere aandoeningen optreden die levensbedreigend zijn.

Philips zet meer in op apparatuur voor de begeleiding van het behandelen van aandoeningen. De omzet daarvan groeit harder dan apparatuur voor diagnostiek.

[verwijderd] 7 augustus 2009 19:03

0

Merck Shareholders Approve Merger With Schering-Plough
Last update: 8/7/2009 11:07:01 AM

WHITEHOUSE STATION, N.J., Aug 07, 2009 (BUSINESS WIRE)
-- Merck & Co. (MRK) today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough (SGP). The preliminary tabulation indicates that more than 99% of shares voted were in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.

"We are gratified by the shareholder confidence demonstrated through the outcome of today's vote," said Richard T. Clark, Merck's Chairman, President and Chief Executive Officer. "On behalf of Merck's Board and management team, I want to thank our shareholders, customers and dedicated employees for their support throughout this process. We look forward to completing the merger with Schering-Plough and to creating a strong, global leader that can make a substantial difference to patients and global healthcare."

As previously announced on March 9, 2009, under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 of a share of new Merck common stock and $10.50 in cash for each share of Schering-Plough. For Merck shareholders, existing Merck share certificates will automatically represent an equal number of shares in the new Merck after completion of the merger.

The company expects the transaction to close in the fourth quarter of 2009, as originally planned. The transaction remains subject to the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the SEC Merger Regulation and certain other foreign jurisdictions.

All proxy cards and ballots submitted at the special meeting were processed by IVS Associates Inc. for final tabulation and certification. Final voting results will be publicly announced promptly after they have been tabulated and certified.

Dirk

[verwijderd] 17 augustus 2009 15:39

0

European Biosimilars Market May Hint At Limited US Threat
Last update: 8/17/2009 9:10:00 AM

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)

--The threat of biosimilars is a hot topic in the U.S. biotech market, but their introduction in Europe may reveal that their effects will be limited. These drugs, which are as close to a generic version as possible for complex biologic drugs, haven't gained traction in Europe because of limited cost savings and worries that they aren't exact copies. The drugs' struggles in the more cost-conscious European market hints that lucrative U.S. biologic drugs may be able to defend their turf.

"Clearly the impact of biosimilars in Europe has not been very dramatic in terms of market share and price," Credit Suisse analyst Michael Aberman said. There is no regulatory pathway for generic biotech drugs, produced through biological processes, but that could change by year-end with a structure similar to that in Europe.

Generic pharmaceuticals - made with chemicals - must show that they have the same active ingredient as the brand-name version. But biologic molecules are often thousands of times bigger, making it extremely hard to make a carbon copy - hence the name, biosimilar.

These drugs, sold as distinct brands, cost more to produce than traditional generic pills, which can cost just pennies. In the U.S., most biologics have years of patent protection remaining, but European patent expirations have led to biosimilars of Amgen Inc.'s (AMGN) anemia treatment Epogen, and Neupogen, which wards off infections in chemotherapy patients. Amgen doesn't actually sell Epogen in Europe, because of a licensing agreement with Johnson & Johnson (JNJ), which sells a similar product called Eprex. But European market share of Amgen's Aranesp, a longer lasting version of Epogen, has remained steady as Amgen responded to biosimilar competition by lowering prices in some countries.

In May, Amgen Chief Executive Kevin Sharer projected that biologics should maintain 30% to 50% of their cash flows in the face of biosimilar competition, a rate that is drastically different from the small-molecule market.

Some European biosimilars have been selling for 18 months, notes Barclays Capital biotech analyst Jim Birchenough, but they have only managed to grab 5% to 10% of the European market on average.

That is a stark comparison to traditional generics that often grab 80% of branded sales in a matter of months. The low biosimilar adoption rate stems from physician concern about imperfect copies causing problems in a patient, and the related cost savings not being worth that risk.

Earlier in the decade, J&J learned a hard lesson when a slight change in the manufacturing process for Eprex seemed to result in severe immune system reactions in hundreds of patients.

Biologic production difficulties have been demonstrated by industry bellwether Genzyme Corp. (GENZ), which faces shortages of its top-selling drugs because of facility contamination and delays in mass production of Pompe-disease treatment Myozyme due to slight differences from smaller batches.

To be sure, the European market could shift as time passes and biosimilars become more common. Some believe they will gain traction in the U.S., simply because cultural differences make it more acceptable to use generics.

"There is historically a lot less generic penetration in Europe," Natixis Bleichroeder analyst Corey Davis said. Even if biosimilars are successful in the U.S., Birchenough at Barclays Capital points out that Epogen and Neupogen are "relatively simple" compared to many biologic drugs. In order to develop copycat versions of more complex drugs, generic companies will have to make significant investments and may need to conduct large clinical trials to convince regulators of their similarity.

Biosimilar makers, which will likely include prominent biotech and pharmaceutical names, may find that it makes more sense to make slightly better versions of the drugs in order to ensure a better return on that investment. "I just don't see the value proposition of doing full clinical development work in order to grab 5% of the market," Birchenough said.

-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com (END) Dow Jones Newswires

Dirk

[verwijderd] 18 augustus 2009 14:03

0

Genmab Shares Dive On Disappointing Drug Trial News
Last update: 8/18/2009 5:24:01 AM

By Gustav Sandstrom
Of DOW JONES NEWSWIRES
STOCKHOLM (Dow Jones)--Shares in Genmab A/S (GEN.KO) fell sharply Tuesday after the Danish biotech company reported disappointing results from studies of a drug candidate, and gave a full-year profit warning.

At 0919 GMT, Genmab's shares were down 26% at DKK155, against a 0.3% rise in the wider market in Copenhagen.

The Copenhagen-based company late Monday said patients suffering from non-Hodgkin's lymphoma (NHL), a type of cancer, showed an overall response rate of 10% when treated with 1000 mg doses of Arzerra.

Analysts said that was a much lower response than expected. "This is a very disappointing response rate which could make difficult a launch of Arzerra in NHL without further...studies," Jyske Bank said in a note to investors. Genmab, which is developing Arzerra together with GlaxoSmithKline (GSK), also cut its 2009 revenue guidance to around 750 million Danish kroner ($142 million) from previously DKK1.2 billion because it would now miss a milestone payment from the UK-based drug company under the cooperation scheme for Arzerra.

It said it now expects an operating loss in 2009 of DKK650 million, compared to DKK400 million previously seen. The profit warning comes only a day before Genmab's second-quarter report, which is due later Tuesday.

Genmab said it and GSK will continue to review the study results and discuss the development strategy in NHL for Arzerra, which is also known as ofatumumab.

"We are committed to the further development of ofatumumab in NHL," Genmab Chief Executive Lisa Drakeman said. Analyst Lars Hatholt at Nordea, who has a buy rating for Genmab, said Tuesday's share price reaction was due more to the disappointing study results than the profit warning.

He said the weak results reduce Genmab's hopes of launching Arzerra for treatment of NHL, but said, even though some investors have seen big commerical potential in Arzerra for treatment of the disease, he thought the share price slump was an overreaction.

Dirk

[verwijderd] 20 augustus 2009 12:02

0

FDA Approves GSK's Hib Vaccine, Hiberix(R)
Last update: 8/19/2009 8:13:00 PM

--Hiberix available for millions of children who need a booster dose against potentially fatal infection

PHILADELPHIA, Aug 19, 2009 /PRNewswire-FirstCall via COMTEX/

-- In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b (Hib), GlaxoSmithKline (GSK) has received accelerated approval from the FDA (Food and Drug Administration) for Hiberix((R)) [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] as a booster dose in children 15 months through four years of age.( )Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.

The Hib vaccine shortage began in 2007 when another vaccine manufacturer temporarily suspended manufacturing of its Hib containing vaccines. This led the CDC (Centers for Disease Control and Prevention) to recommend temporary deferral of the booster dose for healthy children not at increased risk for Hib disease. Earlier this summer, the CDC reinstated the routine Hib booster dose due to an increase in supply. However, supply was not sufficient to support a mass catch-up effort for the millions of children who did not receive the booster dose during the shortage. Hiberix will help restore supply so children who missed the booster dose can get caught-up. Additionally, children coming in for routine visits can receive the Hib booster shot on time.

"We are pleased that we were able to respond to this public health need," said Peter Lammers, Vice President, U.S. Vaccines, GlaxoSmithKline. "GSK was able to act swiftly to increase supply of Hib vaccine so that children can complete the vaccination schedule as recommended by the CDC." The CDC recommends that children receive the complete Hib vaccination series. The series includes a booster dose in the second year of life, in addition to a complete primary series of immunization in infants.

"It is important for children to complete the series of recommended immunizations, including booster shots, to protect them against serious infectious diseases such as Hib," said Jerome Klein, MD, Professor of Pediatrics at Boston University School of Medicine, member of the Division of Pediatric Infectious Diseases at Boston Medical Center.

"The approval and availability of an additional Hib vaccine, for the booster dose will make it possible for children to be fully immunized to prevent serious infectious diseases caused by Hib."

The review of Hiberix for the booster indication was conducted under accelerated approval regulations due to the shortage of Hib vaccine supply in the U.S. GSK submitted safety and efficacy information from clinical studies conducted outside the U.S. for this review. In those studies, a booster dose of Hiberix following primary series vaccination provided protective levels of antibodies against Hib bacteria, regardless of the priming vaccine that was used. More than 54 million doses of Hiberix have been distributed outside the U.S. since the 1996 launch in Germany, and the vaccine is currently registered in nearly 100 countries. The vaccine is expected to be available within several weeks.

Dirk

custom.marketwatch.com/custom/tdameri...

[verwijderd] 20 augustus 2009 16:55

0

up 200% vandaag.

MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
Last update: 8/20/2009 8:00:00 AM

--MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program

WOONSOCKET, R.I., Aug 20, 2009 /PRNewswire-FirstCall via COMTEX/

-- MultiCell Technologies, Inc. (MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays.

MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer. The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies.

"We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets." The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.

voda 24 augustus 2009 16:07

0

Procter & Gamble verkoopt farma-divisie aan Warner Chilcott

CINCINNATI (Dow Jones)--Het Amerikaanse levensmiddelenconcern Procter & Gamble Company kondigt maandag aan de wereldwijde farmaceutische activiteiten te verkopen aan het farmaceutische bedrijf Warner Chilcott plc. De overnameprijs bedraagt $3,1 miljard in contanten. De transactie zal naar verwachting tegen het einde van 2009 worden afgerond.

Het merendeel van de 2.300 medewerkers van het farmaceutische onderdeel van Procter & Gamble zal overgaan naar Warner Chilcott. De activiteiten hadden in de twaalf maanden tot 30 juni 2009 naar schatting een omzet van $2,3 miljard en een nettowinst van $540 miljoen.

De verkoop zal volgens Procter & Gamble een boekwinst opleveren van circa $1,4 miljard na belastingen, ofwel $0,44 per aandeel.

Warner Chilcott stelt de overname te financieren met een lening van een groep van banken. The Wall Street Journal wist zondag al te melden dat zes banken onder leiding van JPMorgan Chase & Co en Bank of America Corp een lening van $4,0 miljard zullen verstrekken aan Warner Chilcott, waarvan zo'n $3,0 miljard voor de overname van de farma-divisie van Procter & Gamble en zo'n $1,0 miljard voor de herfinanciering van de bestaande schuld van Warner Chilcott.

- Door Martijn Mom; Dow Jones Nieuwsdienst; +31-20-5715 201; martijn.mom@dowjones.com

aossa 25 augustus 2009 11:19

0

The new sweet spot for biotech buyouts: $1B to $2B

By John Carroll Comment | Forward

While today's P&G deal underscores that big leveraged buyouts may be returning to favor, Dow Jones went looking for the sweet spot in biotech takeovers. And they landed in the rich field of developers with promising late-stage products in the pipeline that can fetch a bid of $1 billion to $2 billion.

Who qualifies for that profile? The newswire pegs Human Genome Sciences, InterMune and Theravance as likely targets. Medarex, Sciele, CV Therapeutics and Alpharma all sold in that range in the past year. And it's unlikely that the players in the game now are likely to try and match the big mega-mergers that Roche, Pfizer and Merck have all pulled off.

An increase in M&A activity combined with the first stirrings of positive news on the IPO front would help underscore a sense that the biotech industry is on the comeback trail.

Read the report:
blogs.wsj.com/health/2009/08/21/is-1-...

aossa 25 augustus 2009 14:59

0

GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development

* Press Release
* Source: GenVec, Inc.
* On Tuesday August 25, 2009, 7:25 am EDT

GAITHERSBURG, Md., Aug. 25 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC - News) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens.

"This important grant will support work to advance our cell line technology and enhance GenVec's ability to discover and develop new adenovector-based vaccines and therapeutics," said Dr. Doug Brough, GenVec's Executive Director of Vector Sciences.

finance.yahoo.com/news/GenVec-Receive...

www.genvec.com/go.cfm?do=Press.List

voda 25 augustus 2009 17:15

0

Nieuwe groep ziekteverwekkers ontdekt
25 augustus 2009, 17:06 | ANP
NIJMEGEN (ANP) - Onderzoeker Jakko van Ingen van de Radboud Universiteit in Nijmegen heeft een nieuwe groep ziekteverwekkers ontdekt, die voor zeer langdurige longaandoeningen kunnen zorgen. Bij patiënten die toch al beschadigde longen hadden, kan een antibioticakuur van twee jaar nodig zijn. Soms is er geen andere oplossing dan het verwijderen van de zieke long.

De ziekmakende bacterie is de non-tuberculeuze mycobacterie. Deze bacteriefamilie bestaat uit ruim 130 verschillende leden. Ze bevinden zich overal in het milieu en mensen komen er voortdurend mee in aanraking. Van slechts twee familieleden is bekend dat ze lepra dan wel tuberculose kunnen veroorzaken.

Tot nu toe namen artsen aan dat alle andere non-tuberculeuze mycobacteriën onschuldig zijn. Uit het Nijmeegse onderzoek is nu gebleken dat er onder de mycobacteriën veel meer ziekteverwekkers zijn. Longinfecties komen het meeste voor. Nader onderzoek moet uitwijzen hoeveel mycobacteriën er precies zijn en welke schadelijk zijn, zo meldt de universiteit dinsdag op artsennet.nl.

voda 27 augustus 2009 16:14

0

OncoMethylome: test darmkanker sleutel tot succes

Door Patrick Buis

Van DOW JONES NIEUWSDIENST

AMSTERDAM (Dow Jones)--OncoMethylome Sciences' bloedtest voor darmkanker is voor het biotechbedrijf de sleutel naar succes, aangezien het een product betreft voor alle volwassenen boven de 50 jaar, zegt Chief Financial Officer Philip Devine donderdag naar aanleiding van de financiele resultaten van de eerste zes maanden van 2009.

"OncoMethylome verwacht het komend jaar een commerciele overeenkomst te sluiten voor deze test voor colorectorale kanker, die eind 2009 of begin 2010 rond zou moeten zijn", zegt Devine. "Een nieuwe klinische studie met 5.000 patienten ter validatie van de test is inmiddels opgestart", voegt Devine toe. Daarnaast benadrukt hij dat er aanhoudende interesse is van verscheidene potentiele partners voor de distributie van de test.

Verder verwacht het bedrijf binnen zes tot negen maanden een overeenkomst te sluiten voor een test voor blaaskanker.

Na de introductie het afgelopen jaar van drie producten in de Verenigde Staten, respectievelijk een test om vroegtijdige detectie van prostaatkanker te verbeteren, een test voor gepersonaliseerde behandeling bij hersentumoren en een test voor colorectale kanker, wordt de test voor hersentumoren inmiddels ook via Amsterdam in Europa gedistribueerd. Voor de introductie van de andere testen is nog geen tijdslijn vastgelegd.

Eerder op de dag rapporteerde OncoMethylome een stijging van het nettoverlies met 11% tot EUR6,3 miljoen. De omzet daalde in het eerste kwartaal van 2009 naar EUR1,3 miljoen, van EUR1,5 miljoen in dezelfde periode vorig jaar. De kaspositie van de onderneming nam af tot EUR23,7 miljoen, ten opzichte van EUR26,4 miljoen na de eerste drie maanden van 2009.

Onco verwacht voor het volledige jaar een stijging van de uitgaven, voornamelijk voor klinische studies. Als gevolg daarvan verwacht het bedrijf dat het verlies hoger zal zijn dan in 2008.

Door Patrick Buis; Dow Jones Nieuwsdienst +31-20-571-52-01; patrick.buis@dowjones.com

voda 27 augustus 2009 16:34

0

Meeste doden Mexicaanse griep in Brazilië
27 augustus 2009, 6:38 | ANP
SAO PAULO (ANP) - Met 557 doden is Brazilië het land geworden met wereldwijd de meeste slachtoffers van de Mexicaanse griep. Het Braziliaanse ministerie van Volksgezondheid maakte woensdag het jongste dodental bekend.

Het Zuid-Amerikaanse land passeerde de Verenigde Staten, die op 20 augustus 522 slachtoffers van het nieuwe H1N1-virus hadden gemeld.

aossa 31 augustus 2009 12:33

0

Roche buys Lonza’s Singapore biologics plant
By Gareth Macdonald, 31-Aug-2009

Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.

The acquisition is a result of an option provided to Roche’s subsidiary Genentech under a 2006 deal that would have seen Lonza manufacture the Avastin active pharmaceutical ingredient (API) on a contractual basis.

And, while US Food and Drug Administration (FDA) clearance to produce Avastin is not expected until next year, Roche’s decision to exercise its option ahead of the 2012 deadline suggests it is keen to secure biologics capacity, particularly since acquiring Genentech.

Jim Miller, VP of Genentech Singapore, which will run the plant for the time being, stressed the importance of the country as a manufacturing destination, suggesting that “Singapore will play an important role in brining important medicines to patients who need them.”

The facility, which is on a 10 acre site at the Tuas Biomedical Park, houses 80,000 litres of fermentation capacity. Roche said the plant and 230 of its workforce will be integrated into its other local manufacturing operations.

Roche’s interests in Singapore include an Escherichia coli (E.coli) production facility at which it plans to make components for its drug Lucentis when manufacturing operations are cleared by the FDA.

Roche did not respond to in-PharmaTechnologist’s request for additional information.

Singapore attractive for biologics production, Lonza

Lonza, which is busily constructing a second large-scale mammalian cell culture based manufacturing facility in the country, was also positive about its deal with Roche.

A company spokesman told in-PharmaTechnologist that Genentech acquired the plant earlier today but was unable to provide further information for reasons of confidentiality.

He did say that Singapore is an ideal location for complex biologics manufacture due to its “committed work force, excellent education system, competitive cost position and strong IP protection laws.”

tinyurl.com/msk6vg

Misschien horen we straks toch nog iets over STAR?

[verwijderd] 31 augustus 2009 12:56

1

Hou het "misschien " maar op :

100% zeker van niet : Genentech en STAR in 2004/2005 was een hele grote , Farce, waar Jan Piet Snot de aandeelhouder, gedurende zeer lange tijd is ingetrapt!

[verwijderd] 31 augustus 2009 13:01

0

quote:
wilb52 schreef:
Hou het "misschien " maar op :

100% zeker van niet : Genentech en STAR in 2004/2005 was een hele grote , Farce, waar Jan Piet Snot de aandeelhouder, gedurende zeer lange tijd is ingetrapt!

Natuurlijk praat een baissier graag over STAR.
Er zit al enkele jaren geen cent meer in de koers verdisconteerd.

aossa 31 augustus 2009 13:03

0

Ik ben niet goed op de hoogte, maar hebben Roche en DSM geen cross-references?

[verwijderd] 31 augustus 2009 13:09

0

Dus jij gelooft in sprookjes mbt DNA en STAR.

En, enige correctie is op zijn plaats:
IK ben geen baissier , dat zijn ze bij CruSELL, Zelf.
De koers weerspiegelt de gang van zaken bij een onderneming.
Als alles zo goed ging als zijnde voorgespiegeld, stond de koers allang op 30+.

De conclusie is gerechtvaardigd dat elk bedijf , die aandelenkoers heeft , die het verdient, en dat is nu al 2.16 euro lager dan , Voor de dag, van de geweldige cijfers en dito performance tijdens de webcast.
No more no less.
Zelfs op een koers van 18.50 kan ik er al meer terugkopen, dan verkocht.

Dus , praat mij niet over wie hier nu een baissier is.
Dat is het bedrijf , zelf, en niemand anders.

[verwijderd] 31 augustus 2009 13:10

1

quote:
wilb52 schreef:
Hou het "misschien " maar op :

100% zeker van niet : Genentech en STAR in 2004/2005 was een hele grote , Farce, waar Jan Piet Snot de aandeelhouder, gedurende zeer lange tijd is ingetrapt!

Wilb is een bekend biotechneut die zonder inhoud en argumenten kan stellen dat de Star technologie van Crucell geflopt is. Wilb is ook iemand die graag de laatse schaapjes over de dam wil jagen,ze dan scheert en vervolgens zijn 18ooo aandeeltjes van dat `slecht`presterende Crucell wil terugkopen.
Wilb is een wolf in schaapskleren Grrr..

PS maar goed dat je weer terug bent!!
En je weet het af en toe bijharken dat tuintje.

[verwijderd] 31 augustus 2009 13:15

0

Ik zit hier mijn kostbare tijd te verdoen.

Vort meh du gijt, omlaag , wel te verstaan (:->D)

Het schaap: meh meh meh meh.

[verwijderd] 31 augustus 2009 13:16

0

quote:
oudje schreef:
[quote=wilb52]
Hou het "misschien " maar op :

100% zeker van niet : Genentech en STAR in 2004/2005 was een hele grote , Farce, waar Jan Piet Snot de aandeelhouder, gedurende zeer lange tijd is ingetrapt!
[/quote]

Natuurlijk praat een baissier graag over STAR.
Er zit al enkele jaren geen cent meer in de koers verdisconteerd.

Toch zag ik deze week een recent stuk (Japanse vertaling) van Toyobo (april 2008 licentie) waarin deze dit hun klanten aanbood waaruit ik niet de indruk kreeg dat dit nu echt een farce was.

Ik denk dat de huidige koers met wat uitschieters naar boven en beneden wel terecht is bij het ons nu bekende nieuws. Crucell kan zelf wat aan de koers doen wanneer ze met een duidelijk overzicht komen wat betreft alle ontwikkelingen en doen ze dat niet met geen nieuws is het wachten en nog eens wachten.

Heb voor mezelf wat omgeruild voor Genmab.

AEX 937,58 -1,00 -0,11% 21 feb


Germany40^	22.179,70	-0,60%
BEL 20	4.405,39	+0,82%
Europe50^	5.441,66	-0,61%
US30^	43.424,20	0,00%
Nasd100^	21.616,30	0,00%
US500^	6.014,32	0,00%
Japan225^	38.152,90	0,00%
Gold spot	2.935,70	0,00%
EUR/USD	1,0460	0,00%
WTI	70,19	0,00%

HEIJMANS KON	+13,94%
Brunel	+7,40%
TomTom	+3,22%
JDE PEET'S	+2,84%
BESI	+2,31%

EBUSCO HOLDING	-5,03%
THEON INTERNAT	-2,07%
CM.COM	-1,85%
Arcadis	-1,83%
NN Group	-1,82%

Crucell « Terug naar discussie overzicht

Sectornieuws - Biotech en Pharma

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers